Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies
Analytical Biochemistry · 2025
DOI: 10.1016/j.ab.2025.115787 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Analytical Biochemistry, 2025. Verfasst von Sheila Chávez-Valdés und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genetic Engineering and Biotechnology, CIGB, Ave. 31 E/ 158 y 190, P.O. Box. 6162, La Habana, 10600, Cuba. Hauptthemen laut MEDLINE: Immunoglobulin A, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Center for Genetic Engineering and Biotechnology.
Abstract (Originalsprache)
COVID-19 is caused by SARS-CoV-2, first identified in 2019. The Cuban vaccines, Abdala and Mambisa, have demonstrated efficacy in preventing SARS-CoV-2 infection. Immunoglobulin A (IgA) are the main line of defense against pathogens invading the respiratory or digestive tract and its presence in serum can be measured to assess vaccine efficacy. ELISAs are a valuable tool for assessing vaccine immunogenicity. These tests should be validated to ensure their reliability and suitability. The objective of this study was to validate a non-commercial ELISA for the quantification of total anti-RBD IgA in serum samples to support clinical studies. This assay demonstrated high clinical specificity (97.3 %). The accuracy and precision of the assay showed an overall error of less than 20 % at all levels in QCs. Re-evaluation of samples showed a mean difference of less than 30 % in 90.2 % of cases. Anti-RBD IgA titers correlated with viral neutralization titers and percentage inhibition of RBD-ACE2 binding. This assay was found to be highly accurate and reproducible for the quantification of anti-RBD IgA, met the most stringent acceptance criteria and is fit for purpose. It is currently being used to evaluate the immunogenicity of the Abdala and Mambisa vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Genetic Engineering and Biotechnology, CIGB, Ave. 31 E/ 158 y 190, P.O. Box. 6162, La Habana, 10600, Cuba.
- Center for Genetic Engineering and Biotechnology, CIGB, Ave. 31 E/ 158 y 190, P.O. Box. 6162, La Habana, 10600, Cuba; Latin American School of Medicine (ELAM), Carretera Panamericana Km 3 1/2, Carr. Panamericana, La Hab…
- Center for Genetic Engineering and Biotechnology, CIGB, Ave. 31 E/ 158 y 190, P.O. Box. 6162, La Habana, 10600, Cuba. Electronic address: gilda.lemos@cigb.edu.cu.
Förderung
- National Center for Genetic Engineering and Biotechnology
Zitieren
APA
Chávez-Valdés, S., Marichal-Rodríguez, A. K., Chacón-Quintero, Y., Martínez-Rosales, R., Gómez-Hernández, N., Ávila-Díaz, L., Vázquez-Arteaga, A., González-Formental, H., Freyre-Corrales, G., Coizeau-Rodríguez, E., Guillen, G., & Lemos-Pérez, G. (2025). Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2025.115787
Vancouver
Chávez-Valdés S, Marichal-Rodríguez AK, Chacón-Quintero Y, Martínez-Rosales R, Gómez-Hernández N, Ávila-Díaz L, et al. Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies. Analytical Biochemistry. 2025. doi:10.1016/j.ab.2025.115787
BibTeX
@article{ChvezValds2025,
author = {Chávez-Valdés, Sheila and Marichal-Rodríguez, Ana K and Chacón-Quintero, Yahima and Martínez-Rosales, Ricardo and Gómez-Hernández, Nivaldo and Ávila-Díaz, Lismary and Vázquez-Arteaga, Amalia and González-Formental, Hany and Freyre-Corrales, Giselle and Coizeau-Rodríguez, Edelgis and Guillen, Gerardo and Lemos-Pérez, Gilda},
title = {Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies},
journal = {Analytical Biochemistry},
year = {2025},
doi = {10.1016/j.ab.2025.115787}
}
EUVIMED